Background and Purpose: This study aimed to evaluate the efficacy and toxicity of chemotherapy using the modified EOF (oxaliplatin

epirubicin

calcium folinate

5-fluorouracil) regimen in patients with locally advanced gastric cancer. Methods: Thirty patients diagnosed with locally advanced gastric cancer were included into this clinical trial. All these patients received the chemotherapy of modified EOF regimen. This regimen consisted of oxaliplatin at 130 mg/m

2

intravenously (2 h) on day 1

epirubicin at 50 mg/m

2

intravenously (2 h) on day 1

5-fluorouracil at 2 400 mg/m

2

intravenously (48 h). All patients received two to four cycles of chemotherapy. After completing the two cycles of chemotherapy

the clinical efficacy and toxicity of chemotherapy would be evaluated. Results: Thirty patients completed the planned treatment. The clinical efficacy rate was 30.0% (9/30) with 3.3% (1/30) complete response (CR) and 26.7% (8/30) partial response (PR) according to the RECIST criteria. The rates of stable disease (SD) and progressive disease (PD) were 46.7% (14/30) and 23.3% (7/30)

respectively. In the trial

66.7% (20/30) patients underwent surgery

46.7% (14/30) patients had curative gastrectomy

and 20.0% (6/30) patients received palliative gastrectomy. The most common toxicities were leukopenia 53.3% (16/30)

neutropenia 53.3% (16/30)

and anorexia 43.3% (13/30). Conclusion: The EOF regimen is one of the effective and well-tolerated conversional chemotherapy regimens in locally advanced gastric cancer.